Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivey in Subjects with Mild to Moderate Alzheimer's Disease
ID Number 09-0367Principal Investigator(s)
Judith A Neugroschl
Department(s) or Division(s)
Primary Objectives: 1. Evaluate the effect of CERE-110 on cognition 2. Examine the safety of administration of CERE-110 in subjects with mild to moderate Alzheimer's Disease Secondary Objectives: 1. Assess the effect of CERE-110 on cognitive and clinical measures to help better estimate the appropriate sample size for future trials 2. Evaluate the feasibility of conducting a multicenter trial of CERE-110 administration 3. Evaluate FDG-PET and volumetric MRI as potential markers of neurotrophic activity and correlates of efficacy.
Recruiting Patients: Yes